Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2462]

SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients with DCIS, LCIS, and ADH

SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients...

SABCS 2018: Delaying adjuvant chemotherapy associated with worse outcomes for patients with triple-negative breast cancer

SABCS 2018: Delaying adjuvant chemotherapy associated with worse outcomes for patients with triple-negative breast...

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemotherapy

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to...

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Researchers identify mutation in BCL2 protein that causes resistance to venetoclax

ASH 2018: Researchers identify mutation in BCL2 protein that causes resistance to venetoclax

ASH 2018: Disruptions in the gut microbiota before hematopoietic cell transplantation associated with worse outcomes

ASH 2018: Disruptions in the gut microbiota before hematopoietic cell transplantation associated with worse...

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

$ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory DLBCL$

ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory...

ASH 2018: Two studies suggest luspatercept reduces need for blood transfusions

ASH 2018: Two studies suggest luspatercept reduces need for blood transfusions

More from ecancer